Internal Medicine Doctors in Garden City, MI Accepting Medicare

51 Internal Medicine doctors found. Showing 41 - 51

Parameswara Reddy Yaramala, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 916-769-7367

Dr. Zachary Thomas Lemon, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6255 Inkster Rd, Suite 101, Garden City, MI 48135 Phone: 734-421-4850    Fax: 734-421-6635

Ananda Vigneswari Anebarassou, MBBS Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-3300

Dr. Abed L Dabaja, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd # Gme, Garden City, MI 48135 Phone: 734-458-4486

Deepthi Reddy Narala, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486

Shadi Fakhouri, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486    Fax: 734-458-4496

Gordon Shyu, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486

Dr. Ali A Jishi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-3300

Dr. Rashona A. Moss, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486    Fax: 734-458-4496

Hetal V Patel, Internal Medicine Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-3300

Joseph H Park, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-3300

News Archive

AHA statement addresses varied cardiac evaluation and management of transplant patients

As thousands of Americans await a life-saving kidney or liver transplant, medical teams are paying close attention to another organ: their hearts. This month the American Heart Association attempts to bring harmony to the varied cardiac evaluation policies created at U.S. hospitals that assess a patient's overall health before transplant surgery.

Certain ARID1a mutations sensitize some tumors to PARP inhibitor drugs

Mutations in ARID1a, which are common in many cancer types, disrupt DNA damage repair in cancer cells, allowing the cancer to progress. This gene may also be an Achilles' heel when treating certain tumors, according to a team of researchers at The University of Texas MD Anderson Cancer Center.

Cynosure to market Smartlipo MPX LaserBodySculpting Workstation in Korea

Broadening the reach of two of its flagship aesthetic laser products into the Asia Pacific region, Cynosure, Inc. today announced that it has received approval to market the Smartlipo MPX(TM) LaserBodySculpting(SM) Workstation in Korea and the Affirm(TM) Anti-Aging Workstation in the People's Republic of China.

HSP27 protein can indicate lung damage during early stages of COPD

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In Austria alone, there are between 500,000 and 600,000 sufferers; around ninety per cent of cases are the result of smoking. Now, under the leadership of Hendrik Jan Ankersmit, a research team from the University Department of Surgery at MedUni Vienna and the Christian Doppler Laboratory for the Diagnosis and Regeneration of Heart and Thorax Diseases has discovered a protein marker in the blood that can already indicate lung damage during the early stages of COPD, before a decrease in lung volume is detected by a pulmonary function test.

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

Read more Medical News

› Verified 1 days ago

• 1
• 2
• 3(current)